Journal of Critical Care
Volume 24, Issue 1 , Pages 36-42 , March 2009

Neuromuscular transmission: New concepts and agents

  • Hans D. de Boer, PhD

      Affiliations

    • Corresponding Author InformationDepartment of Anaesthesiology, Martini Hospital Groningen, PO Box 30033, 9700 RM, Groningen, The Netherlands. Tel.: +31 50 5247352.

References 

  1. Mencke T, Echternach M, Kleinschmidt S, et al. Laryngeal morbidity and quality of tracheal intubation: a randomized controlled trial. Anesthesiology. 2003;98:1049–1056
  2. Arbous MS, Meursing AEE, van Kleef JW, et al. Impact of anesthesia management characteristics on severe morbidity and mortality. Anesthesiology. 2005;102:257–268
  3. Viby-Mogensen J, Jørgensen BC, Ørding H. Residual curarization in the recovery room. Anesthesiology. 1979;50:539–541
  4. Debaene B, Plaud B, Dilly MP, et al. Residual paralysis in the PACU after a single intubating dose of nondepolarizing muscle relaxant with an intermediate duration of action. Anesthesiology. 2003;98:1042–10485
  5. Berg H, Roed J, Viby-Mogensen J, et al. Residual neuromuscular block is a risk factor for postoperative pulmonary complications. A prospective, randomized, and blinded study of postoperative pulmonary complications after atracurium, vecuronium and pancuronium. Acta Anaesthesiol Scand. 1997;41:1095–1103
  6. Gijsenbergh F, Ramael S, Houwing N, et al. First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide. Anesthesiology. 2005;103:695–703
  7. Shields M, Mirakhur RK, Moppett I, et al. Org 25969 (sugammadex), a selective relaxant binding agent for antagonism of prolonged rocuronium-induced neuromuscular block. Br J Anaesth. 2006;96:36–43
  8. Sorgenfrei IF, Norrild K, Larsen PB, et al. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study. Anesthesiology. 2006;104:667–674
  9. Khunl-Brady K, Rex C, Kjaer CC, et al. Reversal of high dose rocuronium with Org 25969. Eur J Anaesthesiol. 2005;22(suppl S34):121
  10. Vanacker B, Vermeyen K, Struys MRF, et al. Reversal by Org 25969 is not affected by sevoflurane when compared with propofol. Anesth Analg. 2007;104:563–568
  11. de Boer HD, Driessen JJ, Marcus MA, et al. Reversal of rocuronium-induced (1.2 mg/kg) neuromuscular block by Org 25969: a multi-center dose finding and safety study. Anesthesiology. 2007;107:239–244
  12. Suy K, Morias K, Hans P, et al. Fast, effective and safe reversal of rocuronium and vecuronium-induced moderate neuromuscular block by the selective relaxant binding agent Org 25969. Anesthesiology. 2007;106:283–288
  13. Rex C, Khunl-Brady K, Sielenkaemper A, et al. Reversal of high dose rocuronium (1.2 mg/kg) with Org 25969. Anesthesiology. 2005;103:A1129
  14. Sacan O, Klein K, White PF. Sugammadex reversal of rocuronium-induced neuromuscular blockade: a comparison with neostigmine-glycopyrrolate and edrophonium-atropine. Anesth Analg. 2007;104:569–574
  15. Lee C, Jahr JS, Candiotti K, et al. Reversal of profound rocuronium neuromuscular block with sugammadex is faster than recovery from succinylcholine. Anesthesiology. 2007;107:A988
  16. De Kam P, van Kuijk J, Smeets J, et al. Single sugammadex doses up to 32 mg/kg are not associated with QT/QTc prolongation. Anesthesiology. 2007;107:A1580
  17. Staals LM, Snoeck MMJ, Flocton EA, et al. The efficacy of sugammadex in patients with impaired versus normal renal failure. Eur J Anesthesiol. 2007;24(suppl 39):122
  18. Amao R, Zornow MH, McTaggart Cowan R, et al. Sugammadex safely reverses rocuronium-induced blockade in patients with pulmonary disease. Anesthesiology. 2007;107:A1582
  19. Dahl V, Pendeville PE, Hollman MW, et al. Reversal of rocuronium-induced neuromuscular blockade by sugammadex in cardiac patients. Anesthesiology. 2007;107:A1581
  20. Plaud B, Meretoja B, Mirakhur RK, et al. Reversal of rocuronium-induced neuromuscular blockade with sugammadex in paediatric and adult patients. Eur J Anesthesiol. 2007;24(suppl 39):124
  21. McDonagh DL, Benedict PE, Kovac AL, et al. Efficacy and safety of sugammadex for reversal of rocuronium-induced blockade in elderly patients. Anesthesiology. 2007;107:A1583
  22. Sparr HJ, Vermeyen KM, Beaufort AM, et al. Anesthesiology. 2007;106:935–943
  23. Bom A, Bradley M, Cameron K, et al. A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew Chem Int Ed Engl. 2002;41:266–270
  24. Proost JH, Eriksson LI, Mirakhur RK, et al. Urinary, biliary and faecal excretion of rocuronium in humans. Br J Anaesth. 2000;85:717–723
  25. van den Broek L, Wierda JMKH, Smeulers NJ, et al. Clinical pharmacology of rocuronium (ORG 9426): Study of the time course of action, dose requirement, reversibility and pharmacokinetics. J Clin Anesth. 1994;6:288–296
  26. de Boer HD, Driessen JJ, van Egmond J, et al. Non-steroidal neuromuscular blocking agents to re-establish paralysis after reversal of rocuronium-induced neuromuscular block with sugammadex. Can J Anaesth. 2008;55:124–125

PII: S0883-9441(08)00180-9

doi: 10.1016/j.jcrc.2008.08.004

Journal of Critical Care
Volume 24, Issue 1 , Pages 36-42 , March 2009

Article Tools